European Pharmaceutical Review

NOVEMBER 24, 2022

Nivolumab (Opdivo), together with chemotherapy has been recommended in the National Institute for Health and Care Excellence NICE final draft guidance for untreated HER2-negative, advanced or metastatic gastric, gastroesophageal junction (GEJ) or oesophageal adenocarcinoma where tumours express programmed death-1 receptor (PD-L1).

Chemotherapy 105

Chemotherapy Immunity Immunization 105

European Pharmaceutical Review

SEPTEMBER 12, 2023

A T-cell epitope cancer vaccine significantly improved overall survival in non-small cell lung cancer (NSCLC) compared to chemotherapy, Phase III data published in Annals of Oncology has shown. percent with chemotherapy. months for chemotherapy. The overall survival rate at one year with Tedopi was 44.4 percent versus 27.5

Vaccines 98

Vaccines Chemotherapy Immunity Immunization 98

World Pharma News

APRIL 10, 2023

The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies and harsh chemotherapy drugs. Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma.

Chemotherapy 90

Chemotherapy Immunity Immunization 90

European Pharmaceutical Review

APRIL 27, 2023

Blinatumomab significantly improved survival, with the rate increasing from 66 percent to 93 percent, compared to individuals just given prior chemotherapy. Monoclonal antibody ( mAb ) blinatumomab binds to leukaemia cells on one side and to immune cells on the other side.

Chemotherapy 105

Chemotherapy Immunity Immunization 105

European Pharmaceutical Review

MAY 17, 2023

The viral therapy “aims to awaken the patient’s immune system and trigger a healing from within,” Dr Fueyo commented. After injection, patients that respond well develop inflammation inside the tumour, triggering an immune response that first kills the virus.” This makes it difficult to treat the cancer with immunotherapy.

Immunity 98

Immunity Immunization Chemotherapy 98

European Pharmaceutical Review

DECEMBER 12, 2023

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.

Immunity 124

Immunity Immunization Chemotherapy Pharmaceutical Companies 124

Express Pharma

NOVEMBER 28, 2024

The standard of care for RM-NPC in India before Toripalimab was chemotherapy (gemcitabine and cisplatin). Additionally, Toripalimab has also been approved as monotherapy for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy.

Chemotherapy 111

Chemotherapy Immunity Immunization 111

European Pharmaceutical Review

AUGUST 25, 2022

This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. After surgery, strategic combinations of radiotherapy, chemotherapy like temozolomide, and other forms of treatment, such as immunotherapy or the use of an electric field cap, are employed.

Immunity 111

Immunity Immunization Chemotherapy Packaging 111

European Pharmaceutical Review

OCTOBER 1, 2022

A Phase III trial from Shanghai Henlius Biotech is the first study to suggest that the programmed cell death (PD) 1 receptor immune checkpoint inhibitor Hansizhuang (serplulimab) plus chemotherapy can markedly improve survival for extensive-stage small cell lung cancer (ES-SCLC) patients. A follow-up after 12.3 months).

Chemotherapy 98

Chemotherapy Immunity Immunization Hospitals 98

Pharmacy Times

DECEMBER 11, 2024

Assessing pre-treatment TIL levels in young breast cancer patients could help predict response to neoadjuvant chemotherapy.

Immunity 48

Immunity Immunization Chemotherapy 48

STAT

MARCH 6, 2023

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine. Her husband said he had no regrets.

Vaccines 246

Vaccines Bioethics Immunity Immunization 246

Express Pharma

AUGUST 8, 2024

Additionally, when compared to patients in the control arm, patients in the vibostolimab and pembrolizumab fixed-dose combination arm experienced a higher rate of adverse events (AEs) and immune-related AEs. At a pre-planned analysis, data showed that the primary endpoint of overall survival (OS) met the pre-specified futility criteria.

Chemotherapy 105

Chemotherapy Immunity Immunization 105

Express Pharma

AUGUST 22, 2024

Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) is approved in the US as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. The chemotherapy-free regimen showed progression-free survival versus osimertinib.

Chemotherapy 96

Chemotherapy Immunity Immunization 96

pharmaphorum

NOVEMBER 9, 2021

Lung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable non-small cell lung cancer (NSCLC). Some cancer cells contain large amounts of PD-L1, which helps them to evade the body’s immune system.

Chemotherapy 59

Chemotherapy Immunity Immunization 59

pharmaphorum

SEPTEMBER 11, 2022

With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”

Immunity 105

Immunity Immunization Chemotherapy Hospitals 105

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results. Then 487 were part of the BV-AVD group.

Chemotherapy 98

Chemotherapy Immunity Immunization 98

Pharmaceutical Technology

MARCH 30, 2023

The European Commission (EC) has granted approval for Regeneron Pharmaceuticals’ Libtayo (cemiplimab), along with platinum-based chemotherapy, as the first-line treatment for PD-L1 expression positive advanced non-small cell lung cancer (NSCLC) in adult patients.

Chemotherapy 52

Chemotherapy Immunity Immunization 52

pharmaphorum

SEPTEMBER 13, 2022

Crucially, he observed a connection between certain tumours and inflammation, noting that neoplastic tissues were often covered with leukocytes of the immune system. 1942 – Chemotherapy moves from trenches to treatment . 1942 – Chemotherapy moves from trenches to treatment . 1907 – The magic bullet of immunotherapy.

Chemotherapy 98

Chemotherapy Immunity Immunization Documentation 98

European Pharmaceutical Review

JANUARY 26, 2023

CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Could CAR T therapies be manufactured in one day?

Chemotherapy 124

Chemotherapy Immunity Immunization 124

pharmaphorum

OCTOBER 22, 2021

The European Commission has given a green light to Opdivo (nivolumab) with chemotherapy for previously-untreated patients with HER2-negative oesophageal, gastric and gastroesophageal junction (GEJ) cancer whose tumours express the PDL-1 biomarker with a score of five or more. months compared to 11.4 months, respectively.

Chemotherapy 105

Chemotherapy Immunity Immunization 105

European Pharmaceutical Review

MAY 12, 2023

High-magnitude vaccine-induced T cell responses, the focus of the immune response analysis that included a new method to track vaccine-expanded clones, correlated with delayed PDAC recurrence. The personalised neoantigen vaccine was based on uridine mRNA–lipoplex nanoparticles. Rojas et al.

Vaccines 98

Vaccines Immunity Immunization Chemotherapy 98

European Pharmaceutical Review

JULY 13, 2022

Our work is establishing whether it is possible to use allogeneic innate immune cells from a healthy donor to support the immune system of a person with cancer in combatting the condition. T cells are the first line of defence in the immune system to eradicate diseases. such as a chimeric antigen receptor (CAR). In response, ??

Immunity 97

Immunity Immunization Chemotherapy 97

European Pharmaceutical Review

JULY 12, 2022

By binding to both CD19, an antigen expressed on B-cells, and to the CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to CD19-expressing tumours where they can elicit an immune response. “By The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

Immunity 98

Immunity Immunization Chemotherapy 98

pharmaphorum

NOVEMBER 29, 2022

Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. About the interviewee.

Immunity 105

Immunity Immunization Chemotherapy Compounding 105

NY Times

MARCH 31, 2021

A drug that unleashes the immune system offers a rare glimmer of hope for those with a cancer that resists most treatments.

Immunity 83

Immunity Immunization Chemotherapy 83

Pharmacy Times

DECEMBER 19, 2022

Specific immune checkpoint inhibitors added to frontline chemotherapy have transformed modern clinical practice.

Chemotherapy 52

Chemotherapy Immunity Immunization 52

European Pharmaceutical Review

APRIL 10, 2024

While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist.

Immunity 95

Immunity Immunization Chemotherapy Diabetes 95

pharmaphorum

MAY 30, 2022

“An antibody-drug conjugate is where you connect and link a chemotherapy to an antibody,” Verma said. So there’s a Trojan horse-like mechanism to deliver chemotherapy right to the cancer cell.”. While directed chemotherapy isn’t totally free of side effects, it reduces them.

Chemotherapy 116

Chemotherapy Immunity Immunization 116

pharmaphorum

JANUARY 26, 2023

More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy cancer cells. After initial chemotherapy, up to 45% of patients with DLBCL will require a second line treatment, which often involves high-dose chemotherapy and a stem cell transplant.

Chemotherapy 96

Chemotherapy Immunity Immunization Hospitals 96

pharmaphorum

JULY 6, 2021

The interim readout from the 39-patient HERIZON trial found 50% of patients treated with the HER-Vaxx (IMU-131) vaccine on top of chemotherapy achieved a partial response or better, compared to 29% of patients given only chemo.

Vaccines 119

Vaccines Chemotherapy Immunity Immunization 119

European Pharmaceutical Review

OCTOBER 25, 2024

The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. New clinical data has shown a potential best-in-class next-generation antibody-drug conjugate (ADC) can offer promising response rates in extensive-stage small cell lung cancer.

Chemotherapy 97

Chemotherapy Compounding Immunity Immunization 97

LifeProNow

APRIL 6, 2023

Patients were treated with Imfinzi in combination with chemotherapy and bevacizumab followed by Imfinzi , Lynparza and bevacizumabas maintenance therapy.

Chemotherapy 100

Chemotherapy Immunity Immunization 100

epicur

JULY 12, 2023

Chemo Blister Packs For safer, more convenient treatment Epicur® chemotherapy tablets are manufactured in our FDA Registered Outsourcing Facility following cGMP. Personalized care throughout the treatment process We know side effects of chemotherapy treatment can be difficult for your patients and their owners. Targeted drug therapy.

Immunity 85

Immunity Immunization Chemotherapy Vaccines 85

pharmaphorum

JANUARY 27, 2023

Evusheld (tixagevimab and cilgavimab) was cleared by the FDA towards the end of 2021, becoming the first antibody to be authorised for prevention of COVID-19 infection, and it rapidly found use among people with compromised immune systems, such as cancer chemotherapy and organ-transplant patients.

Chemotherapy 135

Chemotherapy Immunity Immunization Vaccines 135

European Pharmaceutical Review

MAY 4, 2023

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. Cancer Ther. 2020; 19(10): 2044–56.

Immunity 98

Immunity Immunization Chemotherapy 98

Express Pharma

FEBRUARY 21, 2024

There are multiple Phase III studies for the ADC in frontline NSCLC in combination with immune checkpoint inhibitors such as Merck’s Keytruda (pembrolizumab) or AstraZeneca’s Imfinzi (durvalumab). GlobalData estimates the drug to earn $3.12 billion by 2029. “ Notably, the non-squamous patient subset had a median PFS of 5.6 months vs. 3.7

Chemotherapy 111

Chemotherapy Labelling Immunity Immunization 111

European Pharmaceutical Review

AUGUST 2, 2024

The approval means TECELRA is indicated for individuals who: have received prior chemotherapy are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive have a tumour that expresses the MAGE-A4-antigen The FDA’s decision was based on results of the Phase II SPEARHEAD-1 (Cohort 1) trial.

Chemotherapy 98

Chemotherapy Immunity Immunization 98